Earnings Update: Here's Why Analysts Just Lifted Their CORONA Remedies Limited (NSE:CORONA) Price Target To ₹2,305
CORONA Remedies Limited (NSE:CORONA) just released its quarterly report and things are looking bullish. The company beat expectations with revenues of ₹4.2b arriving 4.6% ahead of forecasts. Statutory earnings per share (EPS) were ₹9.83, 4.6% ahead of estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, the most recent consensus for CORONA Remedies from three analysts is for revenues of ₹16.7b in 2027. If met, it would imply a decent 13% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to expand 20% to ₹38.90. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹16.4b and earnings per share (EPS) of ₹40.80 in 2027. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts.
Check out our latest analysis for CORONA Remedies
Despite cutting their earnings forecasts,the analysts have lifted their price target 19% to ₹2,305, suggesting that these impacts are not expected to weigh on the stock's value in the long term. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values CORONA Remedies at ₹2,479 per share, while the most bearish prices it at ₹2,175. This is a very narrow spread of estimates, implying either that CORONA Remedies is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of CORONA Remedies'historical trends, as the 18% annualised revenue growth to the end of 2027 is roughly in line with the 19% annual growth over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 12% per year. So although CORONA Remedies is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for CORONA Remedies. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple CORONA Remedies analysts - going out to 2029, and you can see them free on our platform here.
You still need to take note of risks, for example - CORONA Remedies has 1 warning sign we think you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.